Amy Copeland, M.D.
- General Surgery
- Surgical Oncology
- Gastrointestinal Cancers
- Stomach Cancer Surgery
- Soft Tissue and Retroperitoneal Sarcoma
- Robotic Surgery
- HIPEC — Hyperthermic (or Heated) Intraperitoneal Chemotherapy
Assistant Clinical Professor, Department of Surgery
Amy Copeland, M.D., is a surgical oncologist treating gastrointestinal cancers such as stomach, small bowel, colon and appendix as well as soft tissue and retroperitoneal sarcomas. She is experienced in treating cancers that have metastasized within the abdomen with complex cytoreductive surgery and intraperitoneal chemotherapy. Dr. Copeland also utilizes minimally invasive and robotic procedures to help patients recover faster and with less discomfort.
Dr. Copeland is dedicated to providing compassionate, individualized care for patients, with a philosophy centered on open communication to create treatment plans that respect each patient’s goals and values. She joined City of Hope because of its commitment to treating the whole person—mind, body, and spirit—and fostering a sense of community for patients and families.
After obtaining her medical degree at the University of Virginia, Dr. Copeland completed her residency in General Surgery at UCLA, followed by fellowship training in Complex General Surgical Oncology at University of Pittsburgh Medical Center. She also gained international training in gastric surgery during a rotation in South Korea. She has research experience in tumor immunology and adoptive cell therapy at the National Cancer Institute and holds a patent in identification of tumor-targeted immune cells from the peripheral blood. Her work has been published in leading scientific journals, including Science, Cancer Cell, and Nature Medicine.
Location
Orange County Lennar Foundation Cancer Center
Irvine, CA 92618
Education & Experience
Board Certifications
- American Board of Surgery
Degrees
- 2015, M.D., University of Virginia School of Medicine — Charlottesville, VA
Fellowships
- 2023-2025, Fellowship in Complex General Surgery Oncology, University of Pittsburgh Medical Center — Pittsburgh, PA
- 2017-2020, Fellowship in Cancer Immunology and Immunotherapy, National Institutes of Health — Bethesda, MD
Residency
- 2015-2023, General Surgery Residency, University of California Los Angeles — Los Angeles, CA
Professional Experience
- 2025-Present, Assistant Clinical Professor, Division of Surgical Oncology, Department of Surgery, City of Hope Orange County — Irvine, CA
Awards & Memberships
Memberships
- Society of Surgical Oncology
- American College of Surgeons
- Phi Beta Kappa
- Alpha Omega Alpha
Publications
- Eckardt MA, Siena NM, Copeland AR, McCaw TR, et al. Dedicated review of sarcoma pathology is necessary for corroborative diagnosis in nearly half of patients. Surgery. In press.
- Leko V, Groh E, Levi ST, Copeland AR, White BS, Gasmi B, Lee C, Li Y, Hill V, Gurusamy D, Sindiri S Gartner JG, Prickett TD, Parkhurst MR, Lowery FJ, Goff SL, Rosenberg SA, Robbins PF. Utilization of primary tumor samples for cancer neoantigen discovery. JITC. Jan 2025;13(1). doi:10.1136/jitc-2024-010993
- Schlegel C, Copeland AR, Liebzinski M, Hall LB, Myers SP, Holtzman MP, Pingpank JF, Choudry HA, Bartlett DL, Ongchin MC. Patient perspectives of fertility following CRS/HIPEC: An opportunity for improved perioperative counseling. J Surg Res. Dec 2024; 306:122-126. doi: 10.1016/j.jss.2024.12.001
- Saif AS, Sarvestani AL, Teke ME, Copeland AR, Gupta S, Shindorf ML, Eade AV, Juneau P, Jen-Jaques A, Blakely AM, Hernandez JM. Sex and race/ethnicity based trends in matriculation to general surgery residency and associated fellowship programs. J Surg Res. Dec 2024; 304:297-304. doi: 10.1016/j.jss.2024.10.020
- Parkhurst M, Goff SL, Lowery FJ, Beyer RK, Halas H, Robbins PF, Prickett TD, Gartner JJ, Sindiri S, Krishna S, Zacharakis N, Ngo L, Ray S, Bera A, Shepherd R, Levin N, Kim SP, Copeland A, Nah S, Levi S, Parikh N, Kwong M, Klemen ND, Yang JC, Rosenberg SA. Adoptive transfer of personalized neoantigenreactive TCR-transduced T cells in metastatic colorectal cancer: phase 2 trial interim results. Nature Medicine. July 2024. Advance online publication. doi: 10.1038/s41591-024-03109-0
- Yossef R, Krishna S, Sindiri S, Lowery FJ, Copeland AR, Gartner JJ, Parkhurst MR, Parikh NB, Hitscherich KJ, Levi ST, Chatani PD, Zacharakis N, Levin N, Vale NR, Nah SK, Dinerman A, Hill VK, Ray S, Bera A, Levy L, Jia L, Kelly MC, Goff SL, Robbins PF, Rosenberg SA. Phenotypic signatures of circulating neoantigen-reactive CD8+ T cells in patients with metastatic cancers. Cancer Cell. Dec 2023; 41(12):2154-2165.e5. doi: 10.1016/j.ccell.2023.11.005.
- Levi ST, Copeland AR, Nah S, Crystal JS, Ivey GD, Lalani A, Jafferji M, White BS, Parikh NB, Leko V, Krishna S, Lowery F, Prickett TD, Gartner JJ, Jia Li, Li YF, Sachs A, Sindri S, Robinson W, Gasmi B, Yang JC, Goff SL, Rosenberg SA, Robbins PF. Neoantigen Identification and Response to Adoptive Cell Transfer in Anti–PD-1 Naïve and Experienced Patients with Metastatic Melanoma. Clin Cancer Res. Jul 2022;28(14):3042-3052. doi: 10.1158/1078-0432.CCR-21-4499
- Yossef R, Krishna S, Lowery FJ, Copeland AR, Parikh NB, Hitscherich K, Robbins PF, Rosenberg SA. Single-cell analysis of circulating neoantigen-reactive CD8+ T cells allows isolation of novel tumor reactive TCRs [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res. 2022;82(12_Suppl):Abstract nr 2762.
- Lowery FJ*, Krishna S*, Yossef R, Parikh NB, Chatani PD, Zakarakis N, Parkhurst MR, Levin N, Sindari S, Sachs A, Hitscherich KJ, Yu Z, Vale NR, Lu Y, Zheng Z, Jia L, Gartner JJ, Hill VK, Copeland AR, Nah SK, Masi RV, Gasmi B, Kivitz S, Paria BC, Florentin M, Kim SP, Hanada K, Li YF, Ngo LT, Ray S, Shindorf M, Levi ST, Shepard R, Toy C, Parikh AY, Prickett TD, Kelly MC, Beyer R, Goff SL, Yang JC, Robbins PF, Rosenberg SA. Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers. Science. Feb 2022; 375(6583):877-884. doi: 10.1126/science.abl5447.
- Seitter SJ, Sherry RM, Yang JC, Robbins PF, Shindorf ML, Copeland AR, McGowan CT, Epstein M, Shelton TE, Langhan MM, Franco Z, Danforth DN, White DE, Rosenberg SA, Goff SL. Impact of Prior Treatment on the Efficacy of Adoptive Transfer of Tumor Infiltrating Lymphocytes in Patients with Metastatic Melanoma. Clin Can Res. Oct 2021. doi: 10.1158/1078-0432.CCR-21-1171